We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roughly a fifth of cancer clinical trials fail to recruit enough participants, creating a “major barrier to progress” for developing new therapies, according to a paper published in the Journal of the National Cancer Institute. Read More
A Los Angeles area supplement provider has been hit with an FDA warning letter for selling unapproved drugs for conditions ranging from kidney stones to stroke prevention. Read More
Dr. Reddy’s Laboratories has adopted a unique strategy to bypass legal issues surrounding its generic version of Nexium: changing the color of its capsules. Read More
In anticipation of proposed guidance on biosimilar interchangeability, AbbVie is requesting that the FDA hold a hearing to ensure the agency considers all viewpoints. Read More
Nearly a dozen organizations are calling for clarification on a draft FDA plan to label injectable therapies that are meant to be used multiple times by a single patient as products for “single patient–use.” Read More
In observance of the holiday season, Drug Industry Daily will not be published Thursday, Dec. 31 and Friday, Jan. 1. The next issue will be published Monday, Jan. 4. Read More
While Teva Pharmaceutical and Takeda Pharmaceutical have framed a previously disclosed joint venture in Japan as a “partnership,” new details about the arrangement show that Takeda is selling off drugs for stock. Read More
Chimerix’s Brincidofovir Falls Short in Phase 3
Court Oks PharmAthene’s $113M Award Against Siga
Valeant CEO on Medical Leave, Company Execs Take Interim Reins Read More